Cell News and Research

RSS

Shrink enters final phase of commercialization program for StemDisc product line

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it is entering the final phase of its commercialization program for its first cell culturing devices for the StemDisc family of stem cell culturing products.

18 Sep 2010

Scientists discover simple blood test for accurate diagnoses of liver damage

Scientists have discovered that the presence of specific proteins in the blood are indicative of early liver cell damage and can determine the point at which cell death occurred, the type of cell death, and the extent of any damage. This could lead to liver damage being assessed faster and more accurately in the future information which could prove valuable when treating people following drug overdoses.

18 Sep 2010

Lawmakers debate action on stem cell research, public health bills

Sen. Arlen Specter said at a Senate hearing Thursday that Congress should move on allowing the government to fund human embryonic stem cell research "to avoid giving a final say on the issue to a conservative Supreme Court," The Associated Press reports.

18 Sep 2010

Penn study reveals structure of cell division's key molecule

On average, one hundred billion cells in the human body divide over the course of a day. Most of the time the body gets it right but sometimes, problems in cell replication can lead to abnormalities in chromosomes resulting in many types of disorders, from cancer to Down Syndrome.

18 Sep 2010

APC gene mutation affects DNA methylation in colon cancer: Research

Colon cancer is the second most common cancer in the United States and causes more than 50,000 deaths each year. It has been known for some time that mutations in the APC gene occur in more than 85 percent of all sporadic colon cancers. Now researchers at Huntsman Cancer Institute at the University of Utah demonstrate in a study featured today in Cell the mechanism by which mutation of the APC gene affects a cellular process known as DNA methylation.

18 Sep 2010

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Ligand Pharmaceuticals Incorporated announced today that it has transferred exclusive license rights to Proximagen Limited for a series of compound hits related to the CXCR4 target with application for a number of indications including those related to the central nervous system. Ligand will receive an upfront payment and continue to be entitled to receive potential future milestone and royalty payments.

18 Sep 2010

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Conference to discuss frontline of immunological research, its clinical application

The immune system is evolved to protect our body against a variety of infectious agents which can cause serious and often fatal diseases. We now appreciate that the immune system is also involved in surveillance of malignant transformation of normal cells that constitute our body, as well as rejection of transplanted organs.

17 Sep 2010

Cell Therapeutics announces results from Annual Meeting

Cell Therapeutics, Inc. announced today the results from its Annual Meeting of Shareholders held on Thursday, September 16, 2010.

17 Sep 2010

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.

17 Sep 2010

Researchers to develop vaginal microbicide gels to reduce HIV risk

With the support of an $11.8 million, five-year federal grant, researchers at the University of Pittsburgh and their collaborators are developing a quick-dissolving vaginal film containing a powerful drug that reduces the risk of HIV infection, and they plan to begin testing it locally within a year.

17 Sep 2010

76% of Americans oppose cloning human embryos for research

As the U.S. Senate prepares to hold a hearing on human embryonic stem cell research (hESCR), a new public opinion poll shows that a plurality of Americans (47 percent) oppose federal funding of stem cell research that involves destroying human embryos, while only thirty-eight percent (38 percent) support such funding. The poll, conducted by ICR / International Communications Research, surveyed 1,006 adults September 8-14. It was commissioned by the Secretariat of Pro-Life Activities at the U.S. Conference of Catholic Bishops (USCCB).

17 Sep 2010

Vital Therapies expands SILVER clinical trial to Middle East

Vital Therapies, Inc., is pleased to announce that the first subject has been enrolled at National Guard Hospital in Riyadh, Kingdom of Saudi Arabia in the further expansion of its SILVER clinical trial to the Middle East. The trial is evaluating whether VTI's biological cellular therapy product, ELAD, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure.

17 Sep 2010

New genetic analysis technique isolates culprit gene in families with inherited single-gene kidney diseases

A University of Michigan-led research team has identified a gene responsible in some families for a devastating inherited kidney disorder, thanks to a new, faster method of genetic analysis not available even two years ago. The success offers hope that scientists can speed the painstaking search for the genes responsible for many rare diseases and test drugs to treat them.

17 Sep 2010

Shrink Nanotechnologies files patent for CellAlign tissue engineering technology

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that certain patent applications related to its advanced tissue engineering technology platform, CellAlign, have been filed.

17 Sep 2010

Scott & White Healthcare recruits patients for Phase III lung cancer trial

Scott & White Healthcare in Round Rock, Texas is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease's recurrence in previously treated patients. The trial will evaluate the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

17 Sep 2010

Research on signaling pathways may help to design therapy for neurodevelopmental disorders

Researchers at the Center for Neuroscience Research at Children's National Medical Center have discovered that the two major types of signaling pathways activated during brain cell development-the epidermal growth factor receptor pathway and the Notch pathway-operate together to determine how many and which types of brain cells are created during growth and repair in developing and adult brains.

17 Sep 2010

Myrexis to present poster on cancer metabolism inhibitor program

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.

17 Sep 2010

Phosphorus additives leads to health disparities in chronic kidney disease

Processed and fast foods enriched with phosphorus additives may play a role in health disparities in chronic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

17 Sep 2010

Cell News and Research

Shrink enters final phase of commercialization program for StemDisc product line

Scientists discover simple blood test for accurate diagnoses of liver damage

Lawmakers debate action on stem cell research, public health bills

Penn study reveals structure of cell division's key molecule

APC gene mutation affects DNA methylation in colon cancer: Research

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Conference to discuss frontline of immunological research, its clinical application

Cell Therapeutics announces results from Annual Meeting

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Researchers to develop vaginal microbicide gels to reduce HIV risk

76% of Americans oppose cloning human embryos for research

Vital Therapies expands SILVER clinical trial to Middle East

New genetic analysis technique isolates culprit gene in families with inherited single-gene kidney diseases

Shrink Nanotechnologies files patent for CellAlign tissue engineering technology

Scott & White Healthcare recruits patients for Phase III lung cancer trial

Research on signaling pathways may help to design therapy for neurodevelopmental disorders

Myrexis to present poster on cancer metabolism inhibitor program

Phosphorus additives leads to health disparities in chronic kidney disease

How to optimize your cell line development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics